Sidley Austin LLP advised the lead investors on the deal.
HBM Healthcare Investments, Cormorant Asset Management, and Octagon Capital Advisors, with participation from a syndicate of other leading institutional investors, acted as lead investors in NiKang Therapeutics Inc.’s US$200 million equity financing pursuant to the issuance and sale of its Series C Preferred Stock.
NiKang is a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
The Sidley team is led by Mehdi Khodadad (M&A and Private Equity, Picture) and includes Anthony Friedman, Patrick Sims, and Max Chaffetz (M&A and Private Equity).
Law Firms: Sidley Austin LLP;